Applied Genetic Technologies Corp AGTC:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
3.65 0.05   1.39%--93,117349.4K
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. Chart as of 03:59 PM ET 9/22/2017

Latest News Headlines for Applied Genetic Technologies Corp

AGTC to Present at Upcoming Conferences

AGTC to Present at Upcoming Conferences GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today announced management will be participating in the following conferences:

AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017

Applied Genetic Technologies Corporation T: (386) 462-2204 (END) Dow Jones Newswires September 13, 2017 07:00 ET (11:00 GMT)

View more recent headlines

Peers Information HelpAGTC Applied Genetic Technologies Corp vs. Peers

Applied Genetic Technologies Corp
Aptevo Therapeutics Inc
CareDx Inc
CTI BioPharma Corp
Eleven Biotherapeutics Inc
Applied Genetic Technologies Corp
Aptevo Therapeutics Inc
CareDx Inc
CTI BioPharma Corp
Eleven Biotherapeutics Inc
Applied Genetic Technologies Corp
Aptevo Therapeutics Inc
CareDx Inc
CTI BioPharma Corp
Eleven Biotherapeutics Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open3.60
Previous Close3.60
Day High3.65
Day Low3.60
52 Week High11/15/2016 | 10.85
52 Week Low9/15/2017 | 3.50
% Off 52 Week High-66.36%
% Off 52 Week Low4.29%
Beta (5 Yr)1.63
Volatility Avg9/22/2017 | 66.71
10-Day Avg. Volume349,358
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2017 | 0.02
P/E Ratio6/30/2017 | 217.1
Market CapMicro Cap | 66.02M
Shares Outstanding18.09M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short254.82K
Short Ratio1.7
Short % of Float1.68%
As of 8/15/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.